
	Application Number:	10/520,153
	Filing Date:	January 3, 2005
	First Named Inventor:	Annette Martin
	Art Unit:	Unknown
	Examiner Name:	Unknown
Total Number of Pages in this Submission : _____		Attorney Docket Number: UTSG:272US


ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input checked="" type="checkbox"/> Form PTO-1449 <input checked="" type="checkbox"/> References C1-C36 <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts/Requirements <input type="checkbox"/> Declaration(s) _____ <input type="checkbox"/> Copy of Notice of Missing Parts/Requirements	<input type="checkbox"/> Drawings(s) _____ <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Statement under 37 CFR §3.73(b) <input type="checkbox"/> Designation of Patent Practitioners <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below) <input type="checkbox"/> Check in the amount of \$ _____ <input checked="" type="checkbox"/> Authorized to be charged to deposit account if check insufficient or inadvertently omitted Deposit account number: <u>50-1212/UTSG:272US</u> <input type="checkbox"/> Sequence Statement <input type="checkbox"/> Paper Copy of Sequence Listing <input type="checkbox"/> Computer Readable Form (CRF) <input checked="" type="checkbox"/> Postcard <input type="checkbox"/> _____ <input type="checkbox"/> _____
Remarks:		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Fulbright & Jaworski L.L.P.	Customer Number	32425
Signature			
Printed Name	Mark B. Wilson	Reg. No.	37,259
Date	October 19, 2005		

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or Printed Name	Mark B. Wilson	Date	October 19, 2005



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Annette Martin *et al.*

Serial No.: 10/520,153

Filed: January 3, 2005

For: CHIMERIC GB VIRUS B (GBV-B)

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: UTSG:272US

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

October 19, 2005

Date

Mark B. Wilson

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed

in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSG:272US.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Mark B. Wilson
Reg. No. 37,259
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: October 19, 2005

Form PTO-1449 (modified)	Atty. Docket No. UTSG:272US	Serial No. 10/520,153
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Annette Martin <i>et al.</i>	
	Filing Date: January 3, 2005	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	09/587,653		Sanger <i>et al.</i> ,	435	005	06/05/00
	A2	10/189,359		Marten <i>et al.</i> ,	435	235.1	07/03/02
	A3	5,807,670	09/15/98	Muerhoff <i>et al.</i>	5	435	12/21/95
	A4	6,267,437	07/31/01	Morsch <i>et al.</i>	194	296	11/18/99

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Al <i>et al.</i> , "Expression of recombinant hepatitis C virus in non-structural protein 5B escherichia coli," <i>Virus Res</i> 53:141-149, 1998.
	C2	Beames <i>et al.</i> , "Development of a primary tamarin hepatocyte culture system for GB virus-B: a surrogate model for hepatitis C. virus," <i>J. Virol.</i> , 74:11764-11772, 2000.
	C3	Beard <i>et al.</i> "An infectious molecular clone of a japanese genotype 1b hepatitis c virus," <i>Hepatology</i> , 30:316-324 1999.
	C4	Behrens <i>et al.</i> , "Identification and properties of the RNA dependent RNA polymerase of hepatitis C virus," <i>EMBO J</i> , 15:12-22, 1996.
	C5	Chambers <i>et al.</i> , "Yellow fever/Japanese encephalitis chimeric viruses. construction and biological properties," <i>J Virol</i> , 73:3095-3101, 1999.
	C6	Choo <i>et al.</i> , "Vaccination of chimpanzees against infection by the hepatitis C virus," <i>Proc Natl Acad Sci USA</i> , 91:1294-1298, 1994.
	C7	Farci <i>et al.</i> , "Lack of protective immunity against reinfection with hepatitis c virus," <i>Science</i> , 258:135-140. 1992.

25521212.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:272US	Serial No. 10/520,153
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Annette Martin <i>et al.</i>	
		Filing Date: January 3, 2005	Group: Unknown
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C8	Farci <i>et al.</i> , "The natural history of infection with hepatitis C virus (HCV) in chimpanzees: Comparison of serologic responses measured with first- and second-generation assays and relationship to HCV viremia," <i>The Journal of Infectious Diseases</i> , 165:1006-1011, 1992.
	C9	Filocamo <i>et al.</i> , "Chimeric Sindbis viruses dependent on the NS3 protease of hepatitis C virus," <i>J. Virol</i> , 71 1417-1427, 1997.
	C10	Frolov <i>et al.</i> , "Cis-acting RNA elements required for replication of bovine viral diarrhea virus-hepatitis C virus 5' nontranslated region chimeras," <i>RNA</i> 4:1418-1435, 1998.
	C11	GenBank Accession Number U22304.
	C12	Grakoui <i>et al.</i> , "Expression and identification of hepatitis C virus polyprotein cleavage products" <i>J. Virol</i> , 67(3):1385-1395, 1993.
	C13	Grakoui <i>et al.</i> , "Characterization of the hepatitis C virus-encoded serine proteinase: Determination of proteinase-dependent polyprotein cleavage sites" <i>J. Virol</i> , 67(5):2832-2843, 1993.
	C14	Hijikata <i>et al.</i> , "Two distinct protease activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus," <i>J Virol</i> , 67:4665-4675, 1993.
	C15	Honda <i>et al.</i> , "Stability of a stem-loop involving the initiator AUG controls the efficiency of internal initiation of translation on hepatitis C virus RNA," <i>RNA</i> , 2:955-968, 1996.
	C16	Karayiannis <i>et al.</i> , "Studies of GB hepatitis agent in tamarins," <i>Hepatology</i> , 9:186-192, 1989.
	C17	Kim <i>et al.</i> , "Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide," <i>Cell</i> , 87:343-355, 1996.
	C18	Kolykhalov <i>et al.</i> , "Identification of a highly conserved element at the 3' terminus of hepatitis C virus genome RNA," <i>J Virol</i> , 70:3363-3371, 1996.
	C19	Kolykhalov <i>et al.</i> , "Transmission of hepatitis C by intrahepatic inoculation of transcribed RNA," <i>Science</i> , 277:570-574, 1997.
	C20	Landt <i>et al.</i> , "A general method for rapid site-directed mutagenesis using the polymerase chain reaction" <i>Gene</i> , 96:125-128, 1990.
	C21	Lemon and Honda, "Internal ribosome entry sites within the RNA genomes of hepatitis C virus and other flaviviruses," <i>Seminars in Virology</i> , 8:274-288, 1997.

25521212.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:272US	Serial No. 10/520,153
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Annette Martin <i>et al.</i>	
		Filing Date: January 3, 2005	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C22	Lindenbach and Rice, "Genetic interaction of flavivirus nonstructural proteins NS1 and NS4A as a determinant of replicase function" <i>J. Virol</i> , 73:4611-4621, 1999.
	C23	Lu and Wimmer, "Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus," <i>Proc Natl Acad Sci USA</i> , 93:1412-1417, 1996.
	C24	Muerhoff <i>et al.</i> , "Genomic organisation of GB viruses A and B: Two new members of the flaviviridae associated with GB agent hepatitis," <i>J Virol</i> , 69:5621-5630, 1995.
	C25	Pletnev <i>et al.</i> , "Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses," <i>Proc. Natl Acad Sci USA</i> , 89:10532-10536, 1992.
	C26	Reynolds <i>et al.</i> , "Unique features of internal initiation of hepatitis C virus RNA translation," <i>EMBO J</i> , 14:6010-6020, 1995.
	C27	Rijnbrand <i>et al.</i> , "Mutational analysis of the GB virus B internal ribosome entry site," <i>J Virol</i> , 74:773-783, 2000.
	C28	Scarselli <i>et al.</i> , "GB virus B and hepatitis C virus share substrate specificity," <i>J Virol</i> , 71:4985-4989, 1997.
	C29	Schlauder <i>et al.</i> , "Molecular and serological analysis in the transmission of the GB hepatitis agent," <i>J Med Virol</i> , 46:81-90, 1995.
	C30	Shaffer <i>et al.</i> , "A hepatitis A virus deletion mutant which lacks the first pyrimidine-rich tract of the 5' nontranslated RNA remains virulent in primates after direct intrahepatic nucleic acid transfection," <i>J Virol</i> , 69:6600-6604, 1995.
	C31	Simons <i>et al.</i> , "Identification of two flavivirus like genomes in the GB hepatitis agent," <i>Proc Natl Acad Sci</i> , 92:3401-3405, 1995.
	C32	Tanaka <i>et al.</i> , "A novel sequence found at the 3' terminus of hepatitis C virus genome," <i>Biochem Biophys Res Comm</i> , 215:744-749, 1995.
	C33	Todd <i>et al.</i> , "Replication competent picornaviruses with complete genomic RNA 3' non-coding deletions," <i>J Virol</i> , 71:8868-8874, 1997.
	C34	Yanagi <i>et al.</i> , "Transcripts from a single full length cDNA clone of hepatitis c virus are infectious when directly transfected into a liver of a chimpanzee," <i>Proc Natl Acad Sci USA</i> , 94:8738-8743, 1998.

25521212.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:272US	Serial No. 10/520,153
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Annette Martin <i>et al.</i>	
		Filing Date: January 3, 2005	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C35	Yao <i>et al.</i> , "Structure of the hepatitis C virus RNA helicase domain," <i>Nature Structural Biology</i> , 4:463-467, 1997.
	C36	Zhao <i>et al.</i> , "Poliovirus/hepatitis C virus (internal ribosome entry site-core) chimeric viruses: improved growth properties through modification of a proteolytic cleavage site and requirement for core RNA sequence but not for core related polypeptides," <i>J Virol</i> , 73:1546-1554, 1999.

25521212.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.